Background {#Sec1}
==========

*Clostridium difficile* is the leading cause of infectious nosocomial diarrhoea in the United States (US) \[[@CR1]\] and the incidence and severity of *C. difficile* infection (CDI) are increasing \[[@CR2]\]. CDI is associated with significant morbidity and mortality; it represents a large clinical burden due to the resultant diarrhoea and potentially life-threatening complications, including pseudomembranous colitis, toxic megacolon, perforations of the colon and sepsis \[[@CR3]--[@CR5]\]. Up to 25 % of patients suffer from a recurrence of CDI within 30 days of the initial infection. Patients at increased risk of CDI are those who are immuno-compromised, such as those with human immunodeficiency virus (HIV) or who are receiving chemotherapy \[[@CR6]--[@CR8]\], patients receiving broad-spectrum antibiotic therapy \[[@CR9], [@CR10]\] or gastric acid suppression therapy \[[@CR9], [@CR11]\], patients aged over 65 years \[[@CR10]\], patients with serious underlying disease \[[@CR12]\], patients in intensive care units (ICUs) \[[@CR10]\], or patients who have recently undergone non-surgical gastrointestinal procedures or those being tube-fed \[[@CR10]\].

CDI represents a significant economic burden on US healthcare systems. Infected patients have an increased length of hospital stay compared to uninfected patients, besides there are significant costs associated with treating recurrent infections. A few systematic reviews of cost-of-illness studies on CDI cost are available \[[@CR13]--[@CR21]\]. These reviews mainly listed the range of reported cost of their respective observation period or were limited by the small number of included studies or inadequate control for confounding factors. No meta-analysis of large number of cost data in the US has been conducted to date. The cost for patients discharged to long-term care facility (LTCF) and recurrent CDI management are understudied. The cost of case management and total financial burden of CDI treatment in the US is therefore underestimated and remains controversial.

The aim of the current study is to conduct a systematic review and meta-analysis of currently available data to identify and quantify the financial burden attributable to CDI, and to further estimate the total economic burden of CDI hospital management in the US.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

English-language databases with online search tools were searched for to offer maximum coverage of the relevant literature: Medline (via the Ovid interface 1946 to July 2015); EMBASE (via the Ovid interface 1980 to July 2015); The Centre for Review and Dissemination Library (incorporating the DARE, NHS EED, and NHS HTA databases); The Cochrane Library (via the Wiley Online Library) and Health Technology Assessment Database (1989 to July 2015).

We supplemented our data by searching relevant published reports from: National epidemiological agencies, Google search for grey literature and hand searched the reference lists of the included studies. The general search headings identified were: Clostridium difficile, economic, costs, cost analysis, health care costs, length of stay, hospitalization. Examples of the strategy for Medline and EMBASE are listed in Additional file [1](#MOESM1){ref-type="media"}.

Study selection {#Sec4}
---------------

All studies that reported novel direct medical cost and/or indirect costs related to CDI management were included. Review articles, comments, editorials, letters, studies of outbreaks, case reports, posters and articles reporting results from economic modelling of a single treatment measure (i.e. cost effectiveness of faecal transplantation) were excluded in the final analysis. All relevant publications from January 2005 to July 2015 were included in the search. We included the following healthcare settings: hospitals, long-term care facilities and community. Geographical scope covered the US. We did not apply any language restriction. Our predefined inclusion and exclusion criteria are shown in Additional file [1](#MOESM1){ref-type="media"}.

Data extraction {#Sec5}
---------------

Two reviewers (SP, SZ) independently selected the included articles and extracted data. After combining their results, any discrepancies were solved by discussion with HN and MK.

The primary outcomes were CDI-related costs (total costs of those with CDI and other comorbidities) and CDI-attributable costs (total costs of CDI management only, after controlling for the confounders). For studies with control groups (e.g. matched patients without CDI), the CDI-attributable cost extracted was either the cost provided by the articles or calculated by reviewers using the CDI-related cost minus the treatment cost of control groups. The secondary outcome was resource utilization associated with CDI, i.e. CDI-related length of stay (LOS) in hospital and CDI-attributable LOS. The study characteristics of each article were extracted. These included basic publication information, study design, statistical methods, economic data reporting characteristics and population information.

When multiple cost data were presented in a study, we included only one cost estimate for each population subgroup as per the priority below:Matched data \> Unmatched data.Adjusted model results \> Unadjusted model results.Regression model results \> Calculated difference.Total cost/charges \> Subgroup cost/charge (i.e. survivors, died).Median (Interquantile Range: IQR) \> Mean (Standard Deviation, SD).

All costs/charges data were inflated to 2015 US\$ equivalent prices adjusted for the Consumer Price Index. If the price year was not reported, it was assumed to be the last year of the data collection period. In cases where charges were reported without cost-to-charge given, costs were estimated using a cost-to-charge ratio of 0.60, which is commonly used value in US health economic studies \[[@CR22]\].

Meta-analysis and estimation of national impact {#Sec6}
-----------------------------------------------

We carried out meta-analysis for cost studies following a Monte Carlo simulation approach, as reported by Jha et al \[[@CR23]\] and Zimlichman et al \[[@CR17]\], bearing in mind the heterogeneity of the included studies. For each subgroup of CDI, we synthesized the data and reported a point estimate and 90 % confidence intervals (CIs) for the CDI-related cost, CDI-attributable cost and their respective LOS. For each included study, we simulated distribution with pooled results weighted by sample size. We fitted a triangular distribution for each of the included studies based on their reported measures of central tendency and dispersion, i.e. mean and 95 % CI, median and IQR, or median and range. Then we simulated 100,000 sample draws from the modeled distribution of each study. At each iteration, we calculated the weighted average of all included studies. Finally, we reported the mean and 90 % CI from the resulting distribution of the 100,000 weighted average of CDI. This approach facilitated the combination of cost data and eliminated the limitation of combining non-normally distributed data. Monte Carlo simulations were conducted using the Monte Carlo simulation software \@RISK, version 7.0 (Palisade Corp).

We estimated the national financial impact of CDI on the US healthcare system, by determining the potential boundaries. The higher boundary was the total number of CDI cases in the US in 2011 extracted from Lessa et al \[[@CR24]\], while the lower boundary was the result from a meta-analysis to estimate the total burden of CDI cases in the US \[[@CR25]\] (For detailed results see Additional file [1](#MOESM1){ref-type="media"}). The total annual cost of CDI management was calculated multiplying the average cost of management per case of CDI, with the total number of CDI cases per year in the US (Fig. [1](#Fig1){ref-type="fig"}). We assumed that all CDI cases received treatment in hospital. A point estimate of the final cost (with range) was reported based on a Monte Carlo simulation of 100,000 sample draws.Fig. 1Formula for total annual cost calculation

Sensitivity analysis {#Sec7}
--------------------

We extracted the total number of CDI patients and CDI-attributable costs from previous studies \[[@CR25]\] and reviews \[[@CR17], [@CR26]\] to carry out a sensitivity analysis of our total cost estimates.

Quality assessment {#Sec8}
------------------

The quality of the studies included was assessed mainly based on the complexity of the statistical method (Fig. [2](#Fig2){ref-type="fig"}). All studies were included in the final analyses.Fig. 2Quality Assessment Method

Results {#Sec9}
=======

Search results {#Sec10}
--------------

The search strategy identified 2671 references from databases. Seven additional references were identified through other sources. After screening the titles, abstracts and relevant full texts (Fig. [3](#Fig3){ref-type="fig"}), a total of 42 studies were included in this review.Fig. 3PRISMA diagram of economic burden search of C. difficile

Study characteristics {#Sec11}
---------------------

The characteristics of the 42 included studies \[[@CR27]--[@CR68]\] are summarized in Table [1](#Tab1){ref-type="table"}. Cost data collection periods ranged from 1997 to 2012. Most studies (*n* = 27) used national level databases, with 17 used National Independent Sample (NIS) database and the remaining 10 studies extracted data from various national databases. Fifteen studies were conducted at state level, of which 6 studies only collected data in single hospital. All studies reported cost in hospital level of care, no articles identified in LTCF and community. Nearly all identified references were retrospective hospital database studies (*n* = 40) and only 1 study was a prospective observational study \[[@CR29]\] and another study was a decision tree model \[[@CR48]\].Table 1Overview of selected references that assessed economic burden attributable to CDI by type of CDI considered in the USIDReferenceState, cityData collection periodType of CDIPopulationSample size (Total)Sample size (CDI cases)Age of CDI patients\
Mean ± SD or (Range), yearsCDI definition (short)Quality assessmentStatistical methodologyData source1Ali 2012 \[[@CR27]\]National2004--2008Comp.Liver transplant193,7145159\>18ICD-9; 008.45 (Primary Diagnosis-PD, Secondary Diagnosis-SD)LowNo matching; no regressionNationwide Inpatient Sample (NIS)2Ananthakrishnan 2008 \[[@CR28]\]National2003Comp.IBD124,5702804\>18\
CDI: 73^a^;\
CDI-IBD: 54^a^ICD-9; 008.45 (PD)MediumNo matching; regressionNIS3Arora 2011 \[[@CR29]\]Houston2007--2008Req.General8585Horn's Index Score 1&2: 64 ± 19; Horn's Index Score 3&4: 65 ± 15Toxin assayLowNo matching; no regressionSt Luke's Episcopal Hospital4Bajaj 2010 \[[@CR30]\]NationalNational: 2005\
Tertiary: 2002--2006BothCirrhosis83,2301165CDI: 69 ± 20; Cirrhosis-CDI: 61 ± 15ICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS5Campbell 2013 \[[@CR31]\]National2005--2011Comp.GeneralNR4521Renal impairment 72.9 ± 13.4; Advanced Age: 78.7 ± 7.4; Cancer/BMT 69.2 ± 14.0; IBD 61.2 ± 18.3; Cabx exposure 61.2 ± 14.8Toxin assayHighMatching; regressionHealth Facts electronic health record (HER) database6Damle 2014 \[[@CR14]\]National2008--2012Comp.Colorectal surgery84,6481266\>18\
63 ± 17ICD-9; 008.45 (PD, SD)MediumNo matching; regressionUniversity Health System Consortium database7Dubberke 2008 \[[@CR33]\]Missouri2003--2003BothNon-\
Surgical24,69143967(18--101) ^a^Toxin assayHighMatching; regressionBarnes-Jewish Hospital Electronic record8Dubberke 2014 \[[@CR2], [@CR34], [@CR71]\]Missouri2003--2009BothRecurrent CDI3958421\>18Toxin assay or clinical diagnosis for recurrent CDIHighMatching; regressionBarnes-Jewish Hospital Electronic record9Egorova 2015 \[[@CR35]\]National2000--2011Comp.Vascular surgeryNR280868.4ICD-9; 008.45 (PD, SD)HighMatching: regressionNIS10Flagg 2014 \[[@CR36]\]National2004--2008Comp.Cardiac surgery349,1122581All age bandICD-9; 008.45 (SD)HighMatching: regressionNIS11Fuller 2009 \[[@CR37]\]Maryland and California2007--2008 for Maryland 2005--2006 for CaliforniaComp.General37603760--Clinical diagnosisMediumNo matching; regressionHealth Services and Cost Review Commission, Maryland; The Office of State-wide Planning and Development, California12Glance 2011 \[[@CR38]\]National2005--2006Comp.Trauma149,64876869(45--82) ^a^Clinical diagnosisMediumNo matching; regressionNIS13Jiang 2013 \[[@CR39]\]Rhode Islands2010--2011Comp.General225,9996053\>18\
71.4 ± 15.8ICD-9; 008.45 (SD)MediumMatching; no regressionRhode Island's 11 acute-care hospitals14Kim 2012 \[[@CR40]\]National2001--2008Comp.Cystectomy10,856153\>18\
68.49 ± 10.52ICD-9 ; 008.45 (SD)MediumNo matching; regressionNIS15Kuntz 2012 \[[@CR41]\]Colorado2005--2008Comp.General30673067All age band, Outpatient 62.8 ± 19.4;\
Inpatient 69.9 ± 16.3ICD-9 + toxin assayMediumNo matching; regressionKaiser Permanente Colorado and Kaiser Permanente Northwest members16Lagu 2014 \[[@CR42]\]Massachusetts, Boston one hospital2004--2010Comp.Sepsis218,915234870.9 ± 15.1ICD-9; 008.45 (PD, SD) + toxin assayMediumMatching; no regressionBaystate Medical Center (Premier Healthcare Informatics database, a voluntary, fee-supported database)17Lameire 2015National2002--2009Comp.Cardiac surgery512,217421,294\>40\
CABG 65.4 ± 10.5\
VS 66.1 ± 12.3ICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS18Lawrence 2007 \[[@CR44]\]Missouri1997--1999BothICU187276Primary 68.9 (34--93)\
Secondary 58.7 (16--91)Toxin assayMediumNo matching; regressionA 19-bed medical ICU in a Midwestern tertiary care referral center.19Lesperance 2011 \[[@CR45]\]National2004--2006Comp.Elective colonic resections695,01010,077\>18\
All 69.8; Surgery-CDI 68.7ICD-9; 008.45 (SD)MediumNo matching; regressionNIS20Lipp 2012 \[[@CR46]\]New York2007--2008Comp.General4,853,8003883\>17ICD-9; 008.45 (SD)MediumNo matching; regression- The SPARCS database- acute care non-federal hospitals in New York State21Maltenfort 2013 \[[@CR47]\]National2002--2010BothArthroplastyNRNRAll age bandICD-9; 008.45 (PD, SD)LowNo matching; no regressionNIS22McGlone 2012 \[[@CR48]\]National2008Comp.GeneralNRNR\>65ICD-9; 008.45 (SD)LowNo matching; no regressionDecision tree model23Nguyen 2008 \[[@CR49]\]National1998--2004Comp.IBD527,187237247.4 ± 0.2ICD-9; 008.45 (secondary diagnosis)MediumNo matching; regressionNIS24Nylund 2011 \[[@CR50]\]National1997,2000, 2003,2006BothChildren10,495,72821,274CDI 9.5 ± 0.07(SEM)ICD-9; 008.45 (PD, SD)HighMatching: regressionHealthcare Cost and Utilization Project Kids'Inpatient Database25O'Brien 2007 \[[@CR51]\]Massachusetts1999--2003Req.General36921036Primary 70 ± 17.6; Secondary 70 ± 17.2ICD-9; 008.45 (PD, SD)LowNo matching; no regressionMassachusetts hospital discharge data26Pakyz 2011 \[[@CR52]\]National2002--2007Comp.General30,07110,857CDI 61 ± 17ICD-9; 008.45 (SD)HighMatching; regressionUniversity Health System Consorsoum (UHC)27Pant 2012 \[[@CR53]\]National2009BothOrgan transplant (OT)244,9556451\>18,\
OT-CDI 58 ± 16 ^a^; CDI-only 73 ± 22 ^a^ICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS28Pant 2012 (2) \[[@CR54]\]National2009BothRenal disease184,1395151\>18,\
ESRD + CDI 66 ± 14 CDI ONLY 70 ± 17ICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS29Pant 2013 \[[@CR55]\]National2009BothChildren with IBD12,610447\<20,\
15.1 ± 4.1ICD-9; 008.45 (PD, SD)MediumNo matching; regressionThe Healthcare Cost and Utilization Project Kids' Inpatient Database (HCUP-KID)30Peery 2012 \[[@CR56]\]NationalFrom 2009Req.General110,533110,533All age bandICD-9; 008.45 (PD)LowNo matching; no regressionNational Ambulatory Medical Care Survey (NAMCS) and NIS31Quimbo 2013 \[[@CR57]\]National2005--2010Comp.High Risk subgroups21,17726,620\>18\
67.5 ± 17.6ICD-9; 008.45 (PD, SD)HighMatching: regressionHealthCare Integrated Research Database32Reed 2008Pennsylvania2002--2006Comp.High Risk subgroups9164524\>17Hospital acquired CDADLowNo matching; no regressionA large academic community hospital33Sammons 2013 \[[@CR59]\]National2006--2011BothChildren13,29544471--18\
6 (2--13) ^a^ICD-9; 008.45 (PD, SD) + toxin assayHighMatching; regressionFree-standing children's hospitals via the Paediatric Health Information System (PHIS)34Singal 2014 \[[@CR60]\]National2007Comp.Cirrhosis89,6731444All age bandICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS35Song 2008 \[[@CR61]\]Maryland2000--2005BothGeneral9025630\>18\
unmatched 57.6 matched 60.3Toxin assayHighMatching; regressionThe Johns Hopkins hospital36Stewart 2011 \[[@CR62]\]National2007BothGeneral82,21441,207All age band,\
70ICD-9; 008.45 (PD, SD)MediumMatching; no regressionNIS37Tabak 2013 \[[@CR63]\]Pennsylvania2007--2008Comp.General77,257255All 64.8 ± 17.6\
CDI 71.1 ± 14.8Toxin assayHighMatching; regressionSix Pennsylvania hospitals via a clinical research database38VerLee 2012Michigan2002--2008Req.General517,413517,413All age bandICD-9; 008.45 (PD)LowNo matching; no regressionAll Michigan acute care hospitals39Wang 2011 \[[@CR65]\]Pennsylvania2005--2008BothGeneral7,227,78878,273All age bandICD-9; 008.45 (PD, SD)HighMatching; regressionThe Pennsylvania Health Care Cost Containment Council (PHC4) database40Wilson 2013 \[[@CR66]\]National2004--2008Comp.Ileostomy13,245217All age bandICD-9; 008.45 (SD)HighMatching; regressionNIS41Zerey 2007 \[[@CR67]\]National1999--2003BothSurgical1,553,5978113All age band\
70 ^a^mICD-9; 008.45 (PD, SD)MediumNo matching; regressionNIS42Zilberberg 2009 \[[@CR68]\]National2005BothProlonged acute mechanical ventilation64,9103468\>18\
66.7 ± 15.9ICD-9; 008.45 (PD, SD)MediumMatching; no regressionNIS*Abbreviations*: *NR* not reported, *IBD* inflammatory bowel disease, *LOS* length of stay, *ICU* intensive care unit, *retrosp*. retrospective, *Comp*. complicating, *Req*. requiring, both requiring and complicating, *PD* primary diagnosis, *SD* secondary diagnosis^a^ Median (Range)

Most studies (*n* = 15) investigated economic outcomes in all age inpatients. Three studies reported cost data in children less than 20 years old. The mean/median age of the CDI patient groups ranged from 47.4 to 73.0 years. Other studies investigated complicated CDI in high-risk patient groups, such as those with major surgery (*n* = 16), inflammatory bowel diseases (*n* = 2), liver or renal disease (*n* = 4), elderly (*n* = 2) and ICU patients (*n* = 1). There was 1 study each in non-surgical inpatients, sepsis inpatients and patients with prolonged acute mechanical ventilation. There was 1 study focusing only on recurrent CDI in the general population.

The sample sizes of included studies ranged from 85 to 7,227,788, with a median sample size of 83,939. A total of 28.8 million inpatient hospital-days were analysed, of which 1.31 million inpatient hospital-days were CDI patients. The median sample size of CDI population was 2938.

The methods to identify CDI varied according to the type of CDI that was assessed in the study. CDI cases were identified either with laboratory test, i.e. positive *C. diffcile* toxin assay, or hospital discharge diagnosis of C. difficile (primary and/secondary) from administrative datasets using the International Classifications of diseases, Ninth, Clinical Modification, ICD-9-CM 008.45. Clinical diagnosis was also used in two studies.

CDI was classified in three types: Community-onset CDI (CO-CDI) requiring hospitalization, Hospital-onset CDI (HO-CDI) complicating other diseases, or both CDI (Table [2](#Tab2){ref-type="table"}). Most of included studies considered HO-CDI (*n* = 23) or both CDI types (*n* = 17). Only four studies investigated CO-CDI only. However, subgroup data of CO-CDI is also available in studies that reported both CDI types.Table 2Classification of CDI Cases by Setting of AcquisitionCase definitionCriteria for classificationCO-CDI- Discharge code ICD-9-CM 008.45 as Primary diagnosisHO-CDI- Discharge code ICD-9-CM 008.45 as secondary diagnosis, without a primary diagnosis of a CDI-related symptom (e.g. diarrhea)\
- Study population ≥ 48 h of hospitalization\
- Symptom onset and/or positive laboratory assay at least ≥ 48 h hospitalizationBoth CDI- No distinction of settings of acquisition\
- Discharge code ICD-9-CM 008.45 in any position*Abbreviations*: *CO-CDI* community-onset CDI, *HO-CDI* hospital-onset CDI, *ICD-9-CM* The International Classification of Diseases, Ninth Revision, Clinical Modification

CDI costs and LOS {#Sec12}
-----------------

The mean CDI-attributable costs per case of CO-CDI were \$20,085 (Range: \$7513--\$29,662), lower than HO-CDI \$34,149 (Range:\$1522--\$122,318). HO-CDI showed a wider range within which the additional cost for CDI in the general population ranged from \$6893 to \$90,202 and in high risk groups ranged from \$7332 in congestive heart failure patients to \$122,318 in renal impairment patients. The mean CDI-attributable LOS was 5.7 days (Range: 2.1--33.4) for CO-CDI, 7.8 (Range:2.3--21.6) days for HO-CDI, and 13.6 (Range: 2.2--16) days for both groups. Cost data and LOS for individual studies are presented in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 3CDI-attributable costs/charges and CDI-related management costs/chargesAuthor, YearPopulationOutcomeStatisticIncremental CDI-attributable cost/chargesCDI-related cost/chargesNoteSample sizeAttributable cost 2015\$SD or 95 % CISample sizeCDI only cost 2015\$SD, 95 % CI or IQRCO-CDI Inpatient CostArora 2011 \[[@CR29]\]GeneralCostMedian8525,4368525,436O'Brien 2007 \[[@CR51]\]GeneralCostMean401514,736401514,736Peery 2012 \[[@CR56]\]GeneralCostMedian110,5537513110,5537513VeerLee 2012 \[[@CR64]\]GeneralChargesMean68,68674,211120,15668,68674,211120,156Kuntz 2012 \[[@CR41]\]GeneralCostMean1650929480016509294800OutpatientKuntz 2012 \[[@CR41]\]GeneralCostMean131611,87735,923131611,87735,923InpatientO'Brien 2007 \[[@CR51]\]GeneralCostMedian1036726310367263PDVeerLee 2012 \[[@CR64]\]GeneralChargesMean17,41327,46340,48417,41327,46340,484PDO'Brien 2007 \[[@CR51]\]GeneralCostMean332716,94634,655332716,946RehospitalisationSammons 2013 \[[@CR59]\]ChildrenCostMean206019,99315,97324,013206019,99315,97324,013Community onsetAnanthakrishnan 2008 \[[@CR28]\]IBDChargesMedian44,40016,864CDI onlyPant 2013 \[[@CR55]\]IBDChargesMean12,61012,761686818,65544750,050CDI onlyBajaj 2010 \[[@CR30]\]CirrhosisChargesMean58,22070,309CDI onlyQuimbo 2013 \[[@CR57]\]CDI HistoryCostMean186629,66220,79842,30093351,86336,64173,411CDI onlyTotal numbers/Weighted Mean224,61720,085314,14123,322HO-CDI Inpatient CostFuller 2009 \[[@CR37]\]GeneralCostCoefficient128218,466288128218,466288Maryland, SDFuller 2009 \[[@CR37]\]GeneralCostCoefficient247829,980271247829,980271California, SDLipp 2012 \[[@CR46]\]GeneralCostMean382632,050382632,050SDMcGlone 2012 \[[@CR48]\]GeneralCostMedian54,04610,016854712,05554,04610,016854712,055SD Cost-hospital perspective-6 days LOSMcGlone 2012 \[[@CR48]\]GeneralCostMedian54,04611,116947613,36654,04611,116947613,36610 days LOSMcGlone 2012 \[[@CR48]\]GeneralCostMedian54,04612,19410,14614,89654,04612,19410,14614,89614 days LOSO'Brien 2007 \[[@CR51]\]GeneralCostMedian2656663026566630SDVeerLee 2012 \[[@CR64]\]GeneralChargesMean51,27390,202146,76751,27390,202146,767SDJiang 2013 \[[@CR39]\]GeneralCostMedian7264*11,689*121121,751Pakyz 2011 \[[@CR52]\]GeneralCostMean30,071*31,180*10,85764,732UnadjustedPakyz 2011 \[[@CR52]\]GeneralCostMedian30,071*24,456*10,85739,59822,40088,537UnadjustedPakyz 2011 \[[@CR52]\]GeneralCostMean30,071*31,169*10,85764,00063,54164,458AdjustedTabak 2013 \[[@CR63]\]GeneralCostMean10206893136513,61725522,99212,22242,470Campbell 2013 \[[@CR31]\]Age \> = 65CostMean30647536430210,771306448,93267,727Quimbo 2013 \[[@CR57]\]ElderlyCostMean34,73245,74943,27948,35910,93383,00478,54887,713Sammons 2013 \[[@CR59]\]ChildrenCostMean241499,01284,626113,398241499,01284,626113,398Ananthakrishnan 2008 \[[@CR28]\]IBDChargesMedian80,170*7655*280424,623Ananthakrishnan 2008 \[[@CR28]\]IBDChargesMean80,17014,368946719,270--Campbell 2013 \[[@CR31]\]IBDCostMean841522−14,93211,8888440,19444,845Quimbo 2013 \[[@CR57]\]IBDcostMean361811,825985114,181120642,03535,91849,191Ananthakrishnan 2008 \[[@CR28]\]Ulcerative colitis (UC)ChargesMedian184326,750Nguyen 2008 \[[@CR49]\]UCChargesMean43,645*14,749*19643,381RegressionAnanthakrishnan 2008 \[[@CR28]\]Crohn\'s disease (CD)ChargesMedian96122,738Nguyen 2008 \[[@CR49]\]CDChargesMean73,197*14,316*32941,453RegressionReed 2008Digestive disordersChargesMean2394*3670*32090768068Damle 2014 \[[@CR14]\]Colorectal surgeryCostMedian84,64814,64413,70015,589126621,30938,218--Kim 2012 \[[@CR40]\]CystectomyCostMean10,856*25,014*15357,37950,20464,554Lesperance 2011 \[[@CR45]\]Elective colonic resectionChargesMean695,010*84,899*10,077158,401Reed 2008Major bowel proceduresChargesMean1035*25,476*4547,06431,302Wilson 2013 \[[@CR66]\]IleostomyCostMean13,462*20,272*21735,076Wilson 2013 \[[@CR66]\]IleostomyCostCoefficient13,46217,51314,10620,921Egorova 2015 \[[@CR35]\]Vascular surgeryCostMedian450,25114,250470836,84722,91262,903Flagg 2014 \[[@CR36]\]Cardiac surgeryCostMedian5160*19,524*2580213,661AdjustedFlagg 2014 \[[@CR36]\]Cardiac surgeryCostMedian349,122*38,320*258072,730UnadjustedLemaire 2015 \[[@CR43]\]Cardiac surgeryCostMedian421,294*35,968*--72,685CABGLemaire 2015 \[[@CR43]\]Cardiac surgeryCostMedian90,923*59,696*--106,141VSReed 2008OR procedure for infectious /parasitic diseasesChargesMean449*7462*3235,52425,498Glance 2011 \[[@CR38]\]TraumaCostMedian149,656*24,131*76839,296Campbell 2013 \[[@CR31]\]CabxCostMean164118,56710,44826,687164178,94899,739Quimbo 2013 \[[@CR57]\]CabxCostMean17,71638,41335,19541,922442964,24259,14569,780Lagu 2014 \[[@CR42]\]SepsisCostMedian4736579249336665236828,57616,49650,494Reed 2008SepticaemiaChargesMean1211*9141*9222,37820,591Campbell 2013 \[[@CR31]\]Renal impairmentCostMean3236502411188928323650,58672,180Quimbo 2013 \[[@CR57]\]RICostMean22,132122,318111,315134,4055533201,212183,706220,386Ali 2012 \[[@CR27]\]Liver transplantChargesMean193,714*77,361*5159158,038Singal 2014 \[[@CR60]\]CirrhosisChargesMean89,673*23,310*144447,401Reed 2008Congestive Heart FailureChargesMean2542*7332*3514,73813,841Quimbo 2013 \[[@CR57]\]ImmunocompromisedCostMean14,34433,63230,15137,516358673,61266,04882,041Campbell 2013 \[[@CR31]\]Cancer/BMTCostMean782687−6480785578248,28072,605Total numbers/Weighted mean3,020,82734,149207,80149,712Dubberke 2014 \[[@CR2], [@CR34], [@CR71]\]Recurrent CDICostMean395812,163395811,523472826,167Total cost differenceDubberke 2014 \[[@CR2], [@CR34], [@CR71]\]Recurrent CDICostMean395812,692975215,919AdjustedSong 2008 \[[@CR61]\]GeneralCostMedian1260*373*63030,305Stewart 2011 \[[@CR62]\]GeneralCostMean82,414*9670*41,20726,790Wang 2011 \[[@CR65]\]GeneralCostMedian7,227,788*4914*78,27312,081Nylund 2011 \[[@CR50]\]ChildrenChargesMedian3565*15,937*356525,5491997Nylund 2011 \[[@CR50]\]ChildrenChargesMedian4356*20,750*435631,8582000Nylund 2011 \[[@CR50]\]ChildrenChargesMedian5574*23,627*557433,62511,34897,8222003Nylund 2011 \[[@CR50]\]ChildrenChargesMedian7779*23,362*777935,44413,601110,3432006Sammons 2013 \[[@CR59]\]ChildrenCostMean698,61651,30444,74657,969698,61651,30444,74657,969Dubberke 2008 \[[@CR33]\]Non-surgicalCostMedian24,691*11,749*43920,569Raw dataDubberke 2008 \[[@CR33]\]Non-surgicalChargesMedian24,691*23,961*43942,154Raw dataDubberke 2008 \[[@CR33]\]Non-surgicalCostMean24,691317330783815Linear regressionDubberke 2008 \[[@CR33]\]Non-surgicalCostMedian24,691419034218,842Matched casesDubberke 2008 \[[@CR33]\]Non-surgicalCostMean24,691652049108381Linear regression, 180 daysDubberke 2008 \[[@CR33]\]Non-surgicalCostMedian24,691928434235,414Matched cases, 180 daysZerey 2007 \[[@CR67]\]SurgicalChargesMedian1,553,597*59,424*811381,708Zerey 2007 \[[@CR67]\]SurgicalChargesCoefficient1,553,59794,40291,58997,216Multivariate regression analysisZilberberg 2009 \[[@CR68]\]Prolonged acute mechanical ventilation (PAMV)CostMedian64,910*48,065*3468190,188107,689333,290UnadjustedZilberberg 2009 \[[@CR68]\]PAMVCostMean337012,616918616,046346891,03971,306AdjustedLawrence 2007 \[[@CR44]\]ICUCostMedian1872*7043*7615,016ICU stayLawrence 2007 \[[@CR44]\]ICUCostMedian1872*36,095*7660,723Entire hospital stayBajaj 2010 \[[@CR30]\]CirrhosisChargesMean83,23049,460116596,678Maltenfort 2013 \[[@CR47]\]ArthroplastyChargesMedian--43,648--84,87752,498142,827Pant 2012 \[[@CR53]\]Organ transplantChargesMean49,19877,24673,41281,08063,65142,05469,033Pant 2012 (2) \[[@CR54]\]Renal diseaseChargesCoefficient184,13969,67968,33871,02059,79387,982Pant 2013 \[[@CR55]\]IBDChargesMean12,61039,45332,47046,436Total numbers/Weighted Mean10,012,92714,403981,00545,421*Abbreviations*: *CO-CDI* community-onset CDI, *HO-CDI* hospital-onset, *PAMV* prolonged acute mechanical ventilation, *Cabx* concomitant antibiotic use, *UC* ulcerative colitis, *CD* Crohn's disease, *IBD* inflammatory bowel disease, *ICU* intensive care unit, *CABG* coronary artery bypass grafting, *VS* valvular surgery, *BMT*, *PD* primary diagnosis, *SD* secondary diagnosis, *Calculated numbers were marked in Italic, attributable cost = cost of CDI group- cost of control non-CDI group*Table 4CDI-attributable LOS and CDI-related LOSReferencePopulationStatisticCDI VS NO CDI LOS (Days)CDI LOS (Days)Sample sizeValueSD or 95 % CISample sizeValueSD or 95 % CICO-CDI Inpatient daysArora 2011 \[[@CR29]\]Horn's index 1&2Mean3315.116.23315.116.2Arora 2011 \[[@CR29]\]Horn's index 3&4Mean5233.433.35233.433.3Kuntz 2012 \[[@CR41]\]General outpatientMean165010.017.0165010.017.0Kuntz 2012 \[[@CR41]\]General inpatientMean131614.920.9131614.920.9O'Brien 2007 \[[@CR51]\]GeneralMean40156.440156.4Pant 2013 \[[@CR55]\]IBDCoefficient12,6102.11.42.82.11.42.8Peery 2012 \[[@CR56]\]GeneralMedian110,5535.0110,5535.0Quimbo 2013 \[[@CR57]\]CDAD HistoryMean18662.92.43.69338.97.211.0Sammons 2013 \[[@CR59]\]ChildrenMedian20605.64.56.620606.04.0^a^13.0^a^VeerLee 2012 \[[@CR64]\]GeneralMean68,6867.17.068,6867.17.0Weighted Mean202,8415.7189,2985.9HO-CDI inpatient daysJiang 2013 \[[@CR39]\]GeneralMedian7264*8.0*121113.0Lipp 2012 \[[@CR46]\]GeneralMean382612.0382612.0Pakyz 2011 \[[@CR52]\]GeneralMean30,07111.110,85721.121.021.2Tabak 2013 \[[@CR63]\]GeneralMedian10202.30.93.825512.09.0^a^21.0^a^Wang 2013GeneralMedian7,227,788*7.0*78,2736.04.0^a^11.0^a^Campbell 2013 \[[@CR31]\]Age \> = 65Mean30643.01.44.6306421.325.3Quimbo 2013 \[[@CR57]\]ElderlyMean34,7327.87.58.110,93318.818.219.5Sammons 2013 \[[@CR59]\]ChildrenMedian241421.619.323.9241423.012.0^a^44.0^a^Ananthakrishnan 2008 \[[@CR28]\]IBDMedian80,1703.028047.0Campbell 2013 \[[@CR31]\]IBDMean843.0−2.38.38421.019.1Quimbo 2013 \[[@CR57]\]IBDMean36183.32.93.7120612.811.614.2Nguyen 2008 \[[@CR49]\]Crohn's diseaseMean73,197*3.8*3299.5Nguyen 2008 \[[@CR49]\]Ulcerative colitisMean43,645*3.2*1969.9Reed 2008Digestive disordersMean2394*3.0*3206.95.2Damle 2014 \[[@CR14]\]Colorectal surgeryMedian84,6488.48.08.9126613.018.0Lesperance 2011 \[[@CR45]\]Elective colonic resectionMean695,010*11.7*10,07722.6Reed 2008Major bowel proceduresMean1035*10.0*4520.911.3Wilson 2013 \[[@CR66]\]IleostomyMean13,46211.621718.7Campbell 2013 \[[@CR31]\]Cabx exposureMean16417.85.79.9164129.334.7Quimbo 2013 \[[@CR57]\]Concomitant Antibiotic UseMean17,7167.87.48.3442917.917.018.9Lagu 2014 \[[@CR42]\]SepsisMean47365.14.45.7236819.2Reed 2008SepticemiaMean12115.09210.77.6Egorova 2015 \[[@CR35]\]Vascular surgeryMedian450,251*6.7*470815.09.0^a^25.0^a^Flagg 2014 \[[@CR36]\]Cardiac surgeryMedian349,122*10.0*258021.0Glance 2011 \[[@CR38]\]TraumaMedian149,656*10.0*76816.0Lemaire 2015 \[[@CR43]\]Cardiac surgery (CABG)Median421,294*12.0*19.0Lemaire 2015 \[[@CR43]\]Cardiac surgery (VS)Median90,923*16.0*24.0Reed 2008Congestive Heart FailureMean2542*5.0*359.77.0Reed 2008OR procedure for infectious /parasitic diseasesMean449*2.0*3214.78.6Lawrence 2007 \[[@CR44]\]ICUMedian7614.91.0^b^86.0^b^Lawrence 2007 \[[@CR44]\]ICUMedian7638.34.0^b^184.0^b^Ali 2012 \[[@CR27]\]Liver transplantMean193,714*10.1*515917.8Singal 2014 \[[@CR60]\]CirrhosisMean89,673*7.5*144413.9Quimbo 2013 \[[@CR57]\]ImmunocompromisedMean14,3448.47.99.0358622.120.623.7Campbell 2013 \[[@CR31]\]Renal impairmentMean32364.02.95.1323622.728.2Quimbo 2013 \[[@CR57]\]Renal impairmentMean22,13217.316.418.3553337.535.539.6Campbell 2013 \[[@CR31]\]Cancer/BMTMean7824.02.35.778221.318.5Weighted Mean10,120,8647.8168,89213.5Both CO-CDI and HO-CDI inpatient costSong 2008 \[[@CR61]\]GeneralMedian1260*4.0*63022.0Stewart 2011 \[[@CR62]\]GeneralMean82,414*5.1*41,20713.014.0Nylund 2011 \[[@CR50]\]Children, 1997Median35653.035655.03.0^a^14.0^a^Nylund 2011 \[[@CR50]\]Children, 2000Median43564.043566.03.0^a^15.0^a^Nylund 2011 \[[@CR50]\]Children, 2003Median55744.055746.03.0^a^14.0^a^Nylund 2011 \[[@CR50]\]Children, 2006Median77794.077796.03.0^a^15.0^a^Sammons 2013 \[[@CR59]\]ChildrenMedian698,61612.210.613.8698,61610.05.0^a^23.0^a^Bajaj 2010 \[[@CR30]\]CirrhosisMean83,2307.1116514.4Bajaj 2010 \[[@CR30]\]CDI onlyMean58,22012.7Pant 2013 \[[@CR55]\]IBDMean12,6102.21.52.84478.2Dubberke 2008 \[[@CR33]\]Non-surgicalMedian24,691*6.0*43910.02. 0^b^87.0^b^Lawrence 2007 \[[@CR44]\]ICU stayMedian1872*3.1*766.11.0^b^86.0^b^Lawrence 2007 \[[@CR44]\]Hospital stayMedian1872*14.4*7624.52.0^b^184.0^b^Maltenfort 2013 \[[@CR47]\]ArthroplastyMedian--7.0--10.07.0^a^17.0^a^Zerey 2007 \[[@CR67]\]SurgicalMedian1,553,59716.015.616.4811318.0Pant 2012 \[[@CR53]\]Organ transplantMedian49,1989.69.39.963,651Pant 2012 (2) \[[@CR54]\]Renal diseaseCoefficient184,1399.49.29.559,793Zilberberg 2009 \[[@CR68]\]Prolonged acute mechanical ventilationMedian33706.14.97.4346825.015.0^a^40.0^a^Weighted Mean2,718,14313.6957,1759.0*Abbreviations*: *CO-CDI* community-onset CDI, *HO-CDI* Hospital-onset CDI, *PAMV* prolonged acute mechanical ventilation, *Cabx* concomitant antibiotic use, *UC* ulcerative colitis, *CD* Crohn's disease, *IBD* inflammatory bowel disease, *ICU* intensive care unit, *CABG* coronary artery bypass grafting, *VS* valvular surgery, *BMT*, *PD* primary diagnosis, *SD* secondary diagnosis, *Calculated numbers were marked in Italic, attributable cost = cost of CDI group- cost of control non-CDI group*^a^Q1-Q3^b^Min-Max

Using a Monte Carlo simulation, we generated point estimates and 90 % CI for both cost and LOS; the meta-analysis results are shown in Table [5](#Tab5){ref-type="table"}. The total cost of inpatient management of CDI-related disease was \$42,316 (90 % CI: \$39,886--\$44,765) per case, of which the total CDI-attributable cost was \$21,448 (90 % CI: 21,152--21,744) per case. For the inpatient management, the attributable cost for those HO-CDI was \$34,157 (90 % CI: \$33,134--\$35,180), which was 1.5 times as much as CO-CDI management \$20,095 (90 % CI: \$4991--\$35,204).Table 5Meta analysis results of cost and LOS of CDI managementCDI categoryCDI-attributable cost per case\
(2015 US\$)CDI-related cost per case\
(2015 US\$)CDI-attributable LOS per case (Days)CDI-related LOS per case (Days)Weighted mean90 % CIWeighted mean90 %CIWeighted mean90 % CIWeighted mean90 % CICO-CDI20,095499135,20423,32912,52034,1415.74.17.35.74.17.3HO-CDI34,15733,13435,18053,48742,05466,3269.79.79.714.113.015.4Both CO-CDI and HO-CDI17,65017,29218,00946,00042,50249,53310.49.711.011.87.117.6Overall inpatient21,44821,15221,74442,31639,88644,7659.79.69.811.18.713.6*Abbreviations*: *CO-CDI* community-onset CDI, *HO-CDI* Hospital-onset CDI

Similar patterns were observed in LOS data. The total CDI-related LOS was 11.1 days (90 % CI: 8.7--13.6) and CDI-attributable LOS was 9.7 (90 % CI: 9.6--9.8). The HO-CDI patients had longer CDI-attributable LOS 9.7 days (90 % CI: 9.7--9.7) than CO-CDI patients 5.7 days (90 % CI: 4.1--7.3).

CDI annual national impact estimate {#Sec13}
-----------------------------------

The total burden of healthcare facility CDI in US was estimated 293,300 (Range: 264,200--453,000) cases per year \[[@CR25]\]. The total financial burden of CDI inpatient management was estimated to be US\$6.3 (Range: \$1.9--\$7.0) billion in 2015, which required 2.4 million days of hospital stay. The total CDI related disease management cost was nearly doubled at US\$12.4 (Range: \$3.7--\$14.4) billion in 2015 (Table [6](#Tab6){ref-type="table"}). A sensitivity analysis showed that the total CDI-attributable cost ranged from \$1.31 to \$13.61, which covers our estimates (Additional file [1](#MOESM1){ref-type="media"}).Table 6Total cost of CDI management in USTotal number of HCF CDI cases per year (2011) \[[@CR25]\]Mean95 % CIAll population ≥2 years Median293,300264,200322,500 Adults ≥18 Upper boundary288,900261,100316,700 Adults ≥18 Lower boundary133,88791,780195,402Cost per CDI case management (2015 US\$)Weighted Mean90 % CI Overall CDI-attributable cost21,44821,15221,744 Overall CDI-related cost42,31639,88644,765Total cost per year (in Billions, 2015 US\$)Weighted MeanRangeTotal CDI-attributable cost per year6.291.947.01Mean6.295.597.01 Upper boundary6.195.526.88 Lower boundary2.871.944.25Total CDI-related cost per year12.413.6614.44Mean12.415.5914.44 Upper boundary12.2510.4114.18 Lower boundary5.673.668.75*Abbreviations*: *HCF* healthcare facility, *CDI* clostridium difficile infection, *CI* confidence intervals

Quality assessment {#Sec14}
------------------

A summary of the quality assessment for statistical methods in included studies is shown in Additional file [1](#MOESM1){ref-type="media"}. There were 13 studies of high quality, 21 studies with medium quality and 8 low quality studies.

Discussion {#Sec15}
==========

We systematically reviewed 42 published cost studies of CDI case management in the past 10 years (2005--2015) and found a significant financial burden associated with CDI in the US. The total CDI-attributable cost was US\$6.3 billion, which is higher than previously reported (range US\$1.1--4.8 billion) \[[@CR14], [@CR16], [@CR17]\]. The mean cost for CDI-attributable hospitalized patients per case was US\$21,448, nearly half of the mean CDI-related inpatient cost.

This review facilitated a meta-analysis of a large number of cost studies for costs related to CDI management and provided an uncertainty range. Zimlichman et al \[[@CR17]\] applied this method to calculate CDI cost based on cost data from two cost-of-illness studies (O'Brian 2007 \[[@CR51]\] & Kyne 2002 \[[@CR69]\]) and obtained a lower cost \[2012US \$11,285 (\$9118--\$13,574)\] than ours. Our review combined 100-point estimates and ranges from 42 individual studies, which provided more accurate and comprehensive data of the cost result. Despite the methodological heterogeneity in perspectives, treatment procedure and statistical analysis, each included study met our inclusion criteria, which were defined to identify studies that provided real world estimates of costs, therefore the combination of these data with uncertainty range represented a valuable and reliable summary of CDI-related cost.

Furthermore, we evaluated hospital onset CDI and community onset CDI separately. We found that CDI complicating hospitalization cost more than CDI requiring hospitalization and the former had longer attributable hospital stay. Therefore, other factors, such as comorbidity, may contribute to infections and increase the difficulty of CDI treatment.

We estimated that the total cost attributable to CDI management in the US was nearly US\$6.3 (Range: \$1.9--\$7.0) billion, which is similar to Dubberke and Olsen's estimates at \$4.8 billion \[[@CR14]\], but significantly higher than other studies (US\$ 1.5 billion in Zimlichman et al \[[@CR17]\] and \$1.1 billion in Ghantoji et al \[[@CR16]\]). The later studies reported lower attributable cost per case based on a limited number of studies before 2005, which arguably is out-of-date. To compare with the latest review on global CDI cost (Nanwa et al \[[@CR26]\]), this review identified 8 additional studies with recent data. Nanwa et al \[[@CR26]\] found that the mean attributable CDI costs ranged from US\$8911 to US\$30,049, which is similar to our results.

In this study, we only assessed the quality of study emphasizing statistical methods and did not use the modified economic evaluation guideline as other COI systematic reviews. Cost and LOS estimation of healthcare-associated infections has the potential to be misleading if the confounders such as patients' comorbidities or daily severity of illness were not properly controlled for. Using either the matching design or multivariable regression analysis allows to control known confounders and may, in part, address selection bias \[[@CR70]\]. We found that whether advanced statistical methods were used and described was crucial for the assessment of data quality, which has not be fully captured by the existing quality assessment tool. Therefore in this study we assessed quality of included studies using this new method. Moreover, Nanwa et al \[[@CR26]\] has evaluated the methodological completeness of most included studies (34 out of 42); we agree with their recommendations regarding possible improvement of future cost-of-illness study. However, we need to bear in mind that cost effects or excess LOS are still likely to be overestimated if the interval to onset of HAI is not properly accounted for in the study design or analysis \[[@CR70]\].

Our systematic review has some limitations. First, all included studies reported direct medical costs from hospital perspective, therefore indirect cost to patients and society and costs of additional care after hospital discharge, have not been captured. No studies reported indirect cost (productivity loss due to work day losses) of patients or care-givers, and we failed to identify studies assessing cost of CDI in long-term care facilities, where about 9 % of CDI patients were discharged to for an average of 24 days of after-care. This would result in an additional US\$141 million burden on the healthcare system and society due to LTCF transfers \[[@CR14]\]. Second, we did not separate primary CDI from recurrent CDI cost in our review because only two studies reported cost specifically to recurrent CDI \$12,592 (Range: \$9752, \$15,919) \[[@CR2]\]. Moreover, we found it difficult to exactly match the CDI case definition in cost study (e.g. ICD10 Code primary diagnosis and secondary diagnosis) with the case definition in epidemiology studies (e.g. community onset, hospital onset), therefore we did not estimate CDI patients managed at outpatient and community settings due to lack of both epidemiology and economic data. The total costs of CDI management may be higher than our current estimate. Fourth, unlike other published reviews, we did not include cost studies from countries other than the US nor facilitate any international comparison. This study initially aimed to identify cost-of-illness studies in North America, but we did not find any studies reporting cost data from Canada. This is likely because we restricted our search to English language databases. Therefore the cost of CDI management in Canada remains unknown. However, we did not apply any language restrictions to the current review.

Effective prevention can reduce the burden of diseases. Strategies have been promoted such as appropriate use of antimicrobials, use of contact precautions and protective personal equipment to care for infected patients, effective cleaning and disinfection of equipment and the environment, and early recognition of disease as primary prophylaxis \[[@CR71]\]. As CDI is an infectious disease, the population at risk would benefit from an effective vaccine, which is currently under development \[[@CR72], [@CR73]\].

More cost of illness studies for recurrent CDI, or in LTCF, and indirect cost from a societal perspective are needed in the future. We would also recommend that published studies report their methods and include point estimates with uncertainty range. Further economic studies for CDI preventive interventions are needed.

Conclusion {#Sec16}
==========

This review indicates that CDI places a significant financial burden on the US healthcare system. In addition, our findings suggest that the economic burden of CDI is greater than previously reported in the US. This review provides strong evidence to aid policy-making on adequate resource allocation to CDI prevention and treatment in US.
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CDI

:   *clostridium difficile* infection

CIs

:   confidence intervals

CO CDI

:   community-onset CDI

HCF

:   healthcare facility

HIV

:   human immunodeficiency virus

HO-CDI

:   hospital-onset cdi

ICD-9-CM

:   the international classification of diseases, ninth revision, clinical modification

ICUs

:   intensive care units

IQR

:   interquantile range
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:   long-term care facility

NIS

:   national independent sample

SD

:   standard deviation
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:   United States
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